Tutogen Medical, Inc. to Present at the Roth Capital Partners 19th Annual OC Conference
13 February 2007 - 11:00PM
PR Newswire (US)
ALACHUA, Fla., Feb. 13 /PRNewswire-FirstCall/ -- Tutogen Medical,
Inc. (AMEX:TTG), a leading manufacturer of sterile biological
implant products made from human (allograft) and animal (xenograft)
tissue, announced to today that Guy Mayer, President and Chief
Executive Officer, and Robert Johnston, Chief Financial Officer,
will be presenting at the Roth Capital Partners 19th Annual OC
Conference February 21, 2007 at 1:30 p.m. Pacific time. The
conference is being held at The Ritz Carlton Laguna Niguel in Dana
Point, California. About Tutogen Medical, Inc. Tutogen Medical,
Inc. manufactures sterile biological implant products made from
human (allograft) and animal (xenograft) tissue. Tutogen utilizes
its Tutoplast Process(R) of tissue preservation and viral
inactivation to manufacture and deliver sterile bio-implants used
in spinal/trauma, urology, dental, ophthalmology, and general
surgery procedures. The Company's Tutoplast(R) products are sold
and distributed worldwide by Zimmer Spine and Zimmer Dental,
subsidiaries of Zimmer Holdings, Inc., Davol Inc. subsidiary of
C.R. Bard Inc., the Mentor Corporation (Mentor), Coloplast Corp.,
IOP, Inc. and through independent distributors internationally. For
more information, visit the Company's Web site at
http://www.tutogen.com/. Forward-Looking Statement Disclaimer: This
press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements typically are identified by use of terms
such as "may," "will," "should," "plan," "expect," "anticipate,"
"estimate," and similar words, although some forward-looking
statements are expressed differently. These statements include, but
are not limited to, statements made by the Company's Chief
Executive Officer concerning the Company's recent financial
performance and trends of quarterly revenue increases, progress
toward profitability, the potential for growth in sales and
continued market acceptance of the Company's hernia repair, breast
reconstruction and new spine products, potential growth in the
Company's dental and international markets, and management's
excitement about the Company's future opportunities.
Forward-looking statements are based on management's current
expectations and are subject to certain risks and uncertainties
that could cause actual results to differ materially from those set
forth or implied by forward-looking statements. These and other
risks are identified in the Company's filings with the Securities
and Exchange Commission, including the Company's Annual Report on
Form 10-K for the fiscal year ended September 30, 2005, as amended.
All information in this press release is as of the date hereof, and
the Company undertakes no duty to update this information unless
required by law. Contacts: L. Robert Johnston, Jr. Lytham Partners,
LLC Chief Financial Officer Joe Diaz Tutogen Medical, Inc. Joe
Dorame 386-462-0402 Robert Blum 602-889-9700 DATASOURCE: Tutogen
Medical, Inc. CONTACT: L. Robert Johnston, Jr., Chief Financial
Officer of Tutogen Medical, Inc., +1-386-462-0402, ; or Joe Diaz,
Joe Dorame of Robert Blum, all of Lytham Partners, LLC,
+1-602-889-9700, for Tutogen Medical, Inc. Web site:
http://www.tutogen.com/
Copyright
Tutogen Medical (AMEX:TTG)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tutogen Medical (AMEX:TTG)
Historical Stock Chart
From Jul 2023 to Jul 2024